Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer.

Abstract

Docetaxel has a response rate of greater than 30% in first-line treatment of Western patients with advanced non-small cell lung cancer (NSCLC). The goal of this open-label. phase II study was to evaluate the activity and safety profile of docetaxel in Asian patients with inoperable untreated stage III NSCLC. Docetaxel was given at 100 mg/m2 as a 1-h infusion every 3 weeks. Prophylactic dexamethasone was given to reduce hypersensitivity reactions and edema. Thirty-five patients were enrolled in the study. The response rate was 34% (95% CI, 19%-50%) according to intent-to-treat analysis. No complete response was observed. Twenty-four patients (69%) had grade 3 or 4 neutropenia in cycle 1, and febrile neutropenia was seen in 12 patients. Six patients (17%) experienced mild fluid retention. Docetaxel is an active agent in first-line treatment of Asian patients with locally advanced NSCLC, with the main toxicity being neutropenia. Fluid retention was a minor problem in this study.

• Authors: B C Goh, M Lehnert, H L Lim, A W Ng, C C Chan, H L Kong, S C Lee, J Wee, E T Chua, J E Wong
• Journal: Acta oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 39 Issue 2 Pg. 225-9 ( 2000) ISSN: 0284-186X [Print] England
• PMID: 10859016 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiemetics
• Antineoplastic Agents, Phytogenic
• Taxoids
• Docetaxel
• Dexamethasone
• Paclitaxel

Topics

• Adult
• Aged
• Aged, 80 and over
• Antiemetics (administration & dosage)
• Antineoplastic Agents, Phytogenic (adverse effects, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
• Dexamethasone (administration & dosage)
• Docetaxel
• Female
• Fever (chemically induced)
• Humans
• Infusions, Intravenous
• Lung Neoplasms (drug therapy, pathology)
• Male
• Middle Aged
• Neutropenia (chemically induced)
• Paclitaxel (adverse effects, analogs & derivatives, therapeutic use)
• Taxoids
• Treatment Outcome
• Water-Electrolyte Balance (drug effects)